EGFR mutational status and clinical outcome to gefitinib monotherapy in chemonaive non-small-cell lung cancer patients

被引：0
作者：
不详
机构：
来源：
PHARMACOGENOMICS | 2008年 / 9卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1382 / 1382
页数：1
相关论文
共 2 条
[1]   Exon 19 of EGFR mutation in relation to the CA-repeat polymorphism in intron 1 [J].
Sueoka-Aragane, Naoko ;
Imai, Kazue ;
Komiya, Kazutoshi ;
Sato, Akemi ;
Tomimasu, Rika ;
Hisatomi, Takashi ;
Sakuragi, Toru ;
Mitsuoka, Masahiro ;
Hayashi, Shinichiro ;
Nakachi, Kei ;
Sueoka, Eisaburo .
CANCER SCIENCE, 2008, 99 (06) :1180-1187
[2]   Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy [J].
Yang, Chih-Hsin ;
Yu, Chong-Jen ;
Shih, Jin-Yuan ;
Chang, Yeun-Chung ;
Hu, Fu-Chang ;
Tsai, Meng-Chin ;
Chen, Kuan-Yu ;
Lin, Zhong-Zhe ;
Huang, Ching-Ju ;
Shun, Chia-Tung ;
Huang, Chin-Lun ;
Bean, James ;
Cheng, Ann-Lii ;
Pao, William ;
Yang, Pan-Chyr .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (16) :2745-2753
1